Analysis

Citius Pharmaceuticals, Inc. (CTXR) Stock Analysis

Citius Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to CTXR.

websiteCTXR/analysis/CTXR

Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to CTXR.

Stock profile

Ticker

CTXR

Asset type

Stock

Market cap

$15.0M

Sector

Health Technology

Industry

Medical Specialties

Currency

USD

Ticker listings

Citius Pharmaceuticals, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • CTXR primary listing
  • 47N0
  • A40MD0

Latest Citius Pharmaceuticals, Inc. news

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pem...

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gy...

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annua...

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class ...

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Ph...

Research sections

Valuation

Review valuation context for Citius Pharmaceuticals, Inc..

Future growth

Review future growth context for Citius Pharmaceuticals, Inc..

Past performance

Review past performance context for Citius Pharmaceuticals, Inc..

Financial health

Review financial health context for Citius Pharmaceuticals, Inc..

Dividend

Review dividend context for Citius Pharmaceuticals, Inc..

Management

Review management context for Citius Pharmaceuticals, Inc..

Ownership

Review ownership context for Citius Pharmaceuticals, Inc..

Other information

Review other information context for Citius Pharmaceuticals, Inc..

Community

Review community context for Citius Pharmaceuticals, Inc..